Latest News
MEDIA: Neurology Live: Significant Improvements in Progressive Multiple Sclerosis Through Foralumab Treatment
18 October 2023
Significant Improvements in Progressive Multiple Sclerosis Through Foralumab Treatment
Link to original article: Significant Improvements in Progressive Multiple Sclerosis Through Foralumab Treatment (neurologylive.com)
October 18, 2023Marco Meglio
Over a 6-month treatment period, investigators observed either stabilization or improvement on outcomes of Expanded...
Tiziana Life Sciences Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis Treatment
18 October 2023
- Patients In the Intermediate Size Patient Population Expanded Access (EA) Program Will Receive Intranasal Foralumab As Part of the At-Home Dosing Initiative
- Greater Than 1 year Safety Exposure to...
Tiziana Life Sciences Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal Foralumab
16 October 2023
- Numeric improvements were seen across key multiple sclerosis measures, including the Modified Fatigue Impact Scale, Expanded Disability Status Scale, Timed 25-Foot Walk test, Pyramidal...
Tiziana Announces Positive Qualitative Six-Month PET Scan Results With Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed With Non-Active Secondary Progressive MS (na-SPMS)
13 October 2023
- Five out of six patients in FDA authorized Expanded Access Program are showing a qualitative reduction in microglia activation (a key biomarker being observed)
- Foralumab to advance into Phase 2 human clinical trials...
Tiziana Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) at the ECTRIMS Annual Congress
11 October 2023
- Late-breaking poster to be presented titled: “Treatment Of Six Non-Active Secondary Progressive MS With Nasal Anti-CD3 Monoclonal Antibody (Foralumab): Safety, Biomarker, And Disability Outcomes”
NEW YORK, October 11, 2023 -- Tiziana Life Sciences...
Tiziana Life Sciences Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis
26 September 2023
NEW YORK, September 26, 2023 – Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of delivery, today announced that it held an Investigator’s Meeting with principal investigators...
MEDIA: BioWorld: Nasal anti-CD3 antibody improves Alzheimer’s disease in mice
12 September 2023
Sep. 12, 2023
Alzheimer’s disease (AD) has a new candidate for its treatment. Nasal anti-CD3 monoclonal antibody (MAb) reduced microglia activation in the brain of mice without its effect being dependent on the β-amyloid (Aβ) deposits characteristic...
Tiziana Life Sciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
08 September 2023
NEW YORK, September 8, 2023 – Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the Company will virtually present and host...
Study Validating MoA of Intranasal Foralumab in Alzheimer’s Disease Published in the Prestigious Journal PNAS, Following FDA IND Clearance
06 September 2023
- The authors conclude that “nasal anti-CD3 has the potential to be a non-toxic novel immunotherapeutic approach for the treatment of Alzheimer’s disease (AD)”
- FDA has cleared the IND for...
Tiziana Life Sciences Announces Appointment of William A. Clementi as Chief Development Officer
23 August 2023
- Leadership Addition Strengthens Company's Commitment to Advancing Innovative Therapies
NEW YORK, August 23, 2023 -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies...